We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+38.63%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$566M
AUM Growth
-$36.9M
Cap. Flow
-$112M
Cap. Flow %
-19.7%
Top 10 Hldgs %
52.22%
Holding
76
New
5
Increased
6
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$20.6M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.7M
3
ZLAB icon
Zai Lab
ZLAB
+$9.29M
4
OMER icon
Omeros
OMER
+$8.48M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$7.71M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$23.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$22.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.7M
4
BLUE
bluebird bio
BLUE
+$14.8M
5
NVRO
NEVRO CORP.
NVRO
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVTY
76
DELISTED
Invuity, Inc
IVTY
– –
-700,000
Closed -$5.08M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Cormorant Asset Management held 76 positions worth $566M, down 6.1% from $603M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Cormorant Asset Management withdrew a net $112M in Q3 2017, closing 25 positions and reducing 14 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 84% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $12.1M.

  • Cormorant Asset Management's largest Q3 2017 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 388,574 shares worth $12.1M.
  • Cormorant Asset Management added most to Ignyta, Inc. in Q3 2017, an estimated $20.6M increase.
  • Cormorant Asset Management's biggest Q3 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $23.5M.
  • Cormorant Asset Management fully exited Lakefront Biotherapeutics American Depositary Shares in Q3 2017, selling an estimated $22.9M.
  • Cormorant Asset Management's ten largest holdings make up 52% of its $566M portfolio in Q3 2017.
  • Cormorant Asset Management opened 5 new positions and closed 25 in Q3 2017.
  • Cormorant Asset Management's portfolio value fell 6.1% quarter-over-quarter to $566M.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.